Kyverna Therapeutics to raise $319 million in upsized IPO, Health News, ET HealthWorld


Toronto: Gilead-backed Kyverna Therapeutics on Wednesday said it will raise $319 million at a valuation of $898.1 million in an upsized U.S. initial public offering (IPO).

The company said it plans to sell 14.5 million shares at $22 each, higher than its earlier price range of $20-$21 per share.

Kyverna, backed by Gilead Sciences and Bain Capital Life Sciences Opportunities, is a clinical-stage cell therapy company that aims to bring disease-modifying therapeutic benefits to patients suffering from autoimmune diseases.

Its shares will begin trading on Feb. 8 on the Nasdaq under the symbol “KYTX”.

  • Published On Feb 8, 2024 at 10:30 AM IST

Join the community of 2M+ industry professionals

Subscribe to our newsletter to get latest insights & analysis.

Download ETHealthworld App

  • Get Realtime updates
  • Save your favourite articles

Scan to download App


Leave a Reply

Your email address will not be published. Required fields are marked *